Posterior cingulate γ-aminobutyric acid and glutamate/glutamine are reduced in amnestic mild cognitive impairment and are unrelated to amyloid deposition and apolipoprotein E genotype

Neurobiology of Aging

Volumn 36, Issue 1, 2015, Pages 53-59

  Riese, Florian ^a   Gietl, Anton ^a   Zölch, Niklaus ^b   Henning, Anke ^b,c   O'Gorman, Ruth ^d   Kälin, Andrea M ^a   Leh, Sandra E ^a   Buck, Alfred ^e   Warnock, Geoffrey ^e   Edden, Richard A E ^f,g   Luechinger, Roger ^b   Hock, Christoph ^a   Kollias, Spyros ^e   Michels, Lars ^e  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b ETH ZURICH   (Switzerland)

^c MAX PLANCK INSTITUTE FOR BIOLOGICAL CYBERNETICS   (Germany)

^d UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Kenneddy Krieger Institute   (United States)

Author keywords

Alzheimer; APOE; Beta amyloid; Dementia; GABA; Glutamate; Glx; Magnetic resonance spectroscopy; Mild cognitive impairment; MRS; PiB; Posterior cingulate cortex

Indexed keywords

4 AMINOBUTYRIC ACID; AMYLOID; APOLIPOPROTEIN E; BIOLOGICAL MARKER; GLUTAMIC ACID; GLUTAMINE; N ACETYLASPARTIC ACID; PITTSBURGH COMPOUND B; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AMYLOID BETA PROTEIN;

AGED; ALLELE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENOTYPE; HUMAN; LEARNING; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; CINGULATE GYRUS; GENETICS; METABOLISM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; FEMALE; GAMMA-AMINOBUTYRIC ACID; GENOTYPE; GLUTAMIC ACID; GYRUS CINGULI; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; NEUROTRANSMITTER AGENTS;

EID: 84920403220     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.07.030     Document Type: Article

References (57)

1. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Gamst A., Holtzman D.M., Jagust W.J., Petersen R.C., Snyder P.J., Carrillo M.C., Thies B., Phelps C.H. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement. 2011, 7:270-279.
2. Andrews-Zwilling Y., Bien-Ly N., Xu Q., Li G., Bernardo A., Yoon S.Y., Zwilling D., Yan T.X., Chen L., Huang Y. Apolipoprotein E4 causes age- and tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice. J.Neurosci. 2010, 30:13707-13717.
3. Antuono P.G., Jones J.L., Wang Y., Li S.J. Decreased glutamate+ glutamine in Alzheimer's disease detected invivo with 1H-MRS at 0.5 T. Neurology 2001, 56:737-742.
4. Boy F., Evans C.J., Edden R.A.E., Lawrence A.D., Singh K.D., Husain M., Sumner P. Dorsolateral prefrontal γ-aminobutyric acid in men predicts individual differences in rash impulsivity. Biol. Psychiatry 2011, 70:866-872.
5. Chen Y., Durakoglugil M.S., Xian X., Herz J. ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Proc. Natl. Acad. Sci. U.S.A 2010, 107:12011-12016.
6. Coghlan S., Horder J., Inkster B., Mendez M.A., Murphy D.G., Nutt D.J. GABA system dysfunction in autism and related disorders: from synapse to symptoms. Neurosci. Biobehavioral Rev. 2012, 36:2044-2055.
7. Duarte J.M.N., Lei H., Mlynárik V., Gruetter R. The neurochemical profile quantified by invivo 1H NMR spectroscopy. Neuroimage 2012, 61:342-362.
8. Dubois B., Feldman H.H., Jacova C., DeKosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P.J., Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007, 6:734-746.
9. Dubois B., Feldman H.H., Jacova C., Cummings J.L., DeKosky S.T., Barberger-Gateau P., Delacourte A., Frisoni G., Fox N.C., Galasko D., Gauthier S., Hampel H., Jicha G.A., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Sarazin M., de Souza L.C., Stern Y., Visser P.J., Scheltens P. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010, 9:1118-1127.
10. Dumanis S.B., DiBattista A.M., Miessau M., Moussa C.E.H., Rebeck G.W. APOE genotype affects the pre-synaptic compartment of glutamatergic nerve terminals. J.Neurochem. 2013, 124:4-14.
11. Edden R.A.E., Barker P.B. Spatial effects in the detection of gamma-aminobutyric acid: improved sensitivity at high fields using inner volume saturation. Magn. Reson. Med. 2007, 58:1276-1282.
12. Edden R.A.E., Muthukumaraswamy S.D., Freeman T.C.A., Singh K.D. Orientation discrimination performance is predicted by GABA concentration and gamma oscillation frequency in human primary visual cortex. J.Neurosci. 2009, 29:15721-15726.
13. Fayed N., Modrego P.J., Rojas-Salinas G., Aguilar K. Brain glutamate levels are decreased in Alzheimer's disease: a magnetic resonance spectroscopy study. Am. J. Alzheimer's Dis. Other Demen. 2011, 26:450-456.
14. Friedman S.D., Baker L.D., Borson S., Jensen J.E., Barsness S.M., Craft S., Merriam G.R., Otto R.K., Novotny E.J., Vitiello M.V. Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurol. 2013, 70:883-890.
15. Fuchs A., Boesiger P., Schulte R.F., Henning A. ProFit revisited. Magn. Reson. Med. 2013, http://dx.doi.org/10.1002/mrm.24703 [Epub ahead of print].
16. Gao F., Edden R.A.E., Li M., Puts N.A.J., Wang G., Liu C., Zhao B., Wang H., Bai X., Zhao C., Wang X., Barker P.B. Edited magnetic resonance spectroscopy detects an age-related decline in brain GABA levels. Neuroimage 2013, 78:75-82.
17. Gasparovic C., Song T., Devier D., Bockholt H.J., Caprihan A., Mullins P.G., Posse S., Jung R.E., Morrison L.A. Use of tissue water as a concentration reference for proton spectroscopic imaging. Magn. Reson. Med. 2006, 55:1219-1226.
18. Gonzalez-Burgos G., Fish K.N., Lewis D.A. GABA neuron alterations, cortical circuit dysfunction and cognitive deficits in schizophrenia. Neural Plast. 2011, 2011:1-24.
19. Gousias I.S., Rueckert D., Heckemann R.A., Dyet L.E., Boardman J.P., Edwards A.D., Hammers A. Automatic segmentation of brain MRIs of 2-year-olds into 83 regions of interest. Neuroimage 2008, 40:672-684.
20. Graff-Radford J., Kantarci K. Magnetic resonance spectroscopy in Alzheimer's disease. Neuropsychiatr. Dis. Treat 2013, 9:687-696.
21. Hammers A., Koepp M.J., Richardson M.P., Hurlemann R., Brooks D.J., Duncan J.S. Grey and white matter flumazenil binding in neocortical epilepsy with normal MRI. A PET study of 44 patients. Brain 2003, 126:1300-1318.
22. Hancu I. Optimized glutamate detection at 3T. J.Magn. Reson. Imaging 2009, 30:1155-1162.
23. Henning A., Schär M., Schulte R.F., Wilm B., Pruessmann K.P., Boesiger P. SELOVS: brain MRSI localization based on highly selective T1- and B1- insensitive outer-volume suppression at 3T. Magn. Reson. Med. 2008, 59:40-51.
24. Hixson J.E., Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J.Lipid Res. 1990, 31:545-548.
25. 1H MRS. NMR Biomed. 2013, 26:329-335.
26. Huang Y., Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 2012, 148:1204-1222.
27. Hutton C., Draganski B., Ashburner J., Weiskopf N. Acomparison between voxel-based cortical thickness and voxel-based morphometry in normal aging. Neuroimage 2009, 48:371-380.
28. Kantarci K., Knopman D.S., Dickson D.W., Parisi J.E., Whitwell J.L., Weigand S.D., Josephs K.A., Boeve B.F., Petersen R.C., Jack C.R. Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. Radiology 2008, 248:210-220.
29. Kantarci K., Lowe V., Przybelski S.A., Senjem M.L., Weigand S.D., Ivnik R.J., Roberts R., Geda Y.E., Boeve B.F., Knopman D.S., Petersen R.C., Jack C.R. Magnetic resonance spectroscopy, amyloid load, and cognition in a population-based sample of cognitively normal older adults. Neurology 2011, 77:951-958.
30. Kantarci K. Proton MRS in mild cognitive impairment. J.Magn. Reson. Imaging 2013, 37:770-777.
31. Kantarci K., Weigand S.D., Przybelski S.A., Preboske G.M., Pankratz V.S., Vemuri P., Senjem M.L., Murphy M.C., Gunter J.L., Machulda M.M., Ivnik R.J., Roberts R.O., Boeve B.F., Rocca W.A., Knopman D.S., Petersen R.C., Jack C.R. MRI and MRS predictors of mild cognitive impairment in a population-based sample. Neurology 2013, 81:126-133.
32. LanctÔt K.L., Herrmann N., Mazzotta P., Khan L.R., Ingber N. GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. Can J. Psychiatry 2004, 49:439-453.
33. Londono A.C., Castellanos F.X., Arbelaez A., Ruiz A., Aguirre-Acevedo D.C., Richardson A.M., Easteal S., Lidbury B.A., Arcos-Burgos M., Lopera F. H-MRS framework predicts the onset of Alzheimer's disease symptoms in PSEN1 mutation carriers. Alzheimer's Dement. 2013, http://dx.doi.org/10.1016/j.jalz.2013.08.282 [Epub ahead of print].
34. Michels L., Martin E., Klaver P., Edden R., Zelaya F., Lythgoe D.J., Lüchinger R., Brandeis D., O'Gorman R.L. Frontal GABA levels change during working memory. PLoS One 2012, 7:e31933.
35. Modrego P.J., Fayed N., Pina M.A. Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. Am. J. Psychiatry 2005, 162:667-675.
36. Morris J.C., Heyman A., Mohs R.C., Hughes J.P., van Belle G., Fillenbaum G., Mellits E.D., Clark C. The Consortium to Establish a Registry for Alzheimer"s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989, 39:1159-1165.
37. Mullins P.G., McGonigle D.J., O'Gorman R.L., Puts N.A.J., Vidyasagar R., Evans C.J., Cardiff Symposium on MRS of GABA, Edden R.A. Current practice in the use of MEGA-PRESS spectroscopy for the detection of GABA. Neuroimage 2014, 86:43-52.
38. Muthukumaraswamy S.D., Edden R.A.E., Jones D.K., Swettenham J.B., Singh K.D. Resting GABA concentration predicts peak gamma frequency and fMRI amplitude in response to visual stimulation in humans. Proc. Natl. Acad. Sci. U.S.A 2009, 106:8356-8361.
39. Northoff G., Walter M., Schulte R.F., Beck J., Dydak U., Henning A., Boeker H., Grimm S., Boesiger P. GABA concentrations in the human anterior cingulate cortex predict negative BOLD responses in fMRI. Nat. Neurosci. 2007, 10:1515-1517.
40. Price J.C., Klunk W.E., Lopresti B.J., Lu X., Hoge J.A., Ziolko S.K., Holt D.P., Meltzer C.C., DeKosky S.T., Mathis C.A. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J.Cereb. Blood Flow Metab. 2005, 25:1528-1547.
41. Provencher S.W. Estimation of metabolite concentrations from localized invivo proton NMR spectra. Magn. Reson. Med. 1993, 30:672-679.
42. Puts N.A.J., Edden R.A.E. Invivo magnetic resonance spectroscopy of GABA: a methodological review. Prog. Nucl. Magn. Reson. Spectrosc. 2012, 60:29-41.
43. Rae C.D. Aguide to the metabolic pathways and function of metabolites observed in human brain 1H magnetic resonance spectra. Neurochem. Res. 2014, 39:1-36.
44. Rupsingh R., Borrie M., Smith M., Wells J.L., Bartha R. Reduced hippocampal glutamate in Alzheimer disease. Neurobiol. Aging 2011, 32:802-810.
45. Sheline Y.I., Raichle M.E., Snyder A.Z., Morris J.C., Head D., Wang S., Mintun M.A. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol. Psychiatry 2010, 67:584-587.
46. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.V., Phelps C.H. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement. 2011, 7:280-292.
47. Sperling R.A., Laviolette P.S., O'Keefe K., O'Brien J., Rentz D.M., Pihlajamaki M., Marshall G., Hyman B.T., Selkoe D.J., Hedden T., Buckner R.L., Becker J.A., Johnson K.A. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009, 63:178-188.
48. Sumner P., Edden R.A.E., Bompas A., Evans C.J., Singh K.D. More GABA, less distraction: a neurochemical predictor of motor decision speed. Nat. Neurosci. 2010, 13:825-827.
49. Tkác I., Starcuk Z., Choi I.Y., Gruetter R. Invivo 1H NMR spectroscopy of rat brain at 1 ms echo time. Magn. Reson. Med. 1999, 41:649-656.
50. Tumati S., Martens S., Alemán A. Magnetic resonance spectroscopy in mild cognitive impairment: systematic review and meta-analysis. Neurosci. Biobehavioral Rev. 2013, 37(10 Pt 2):2571-2586.
51. Vandenberghe R., Van Laere K., Ivanoiu A., Salmon E., Bastin C., Triau E., Hasselbalch S., Law I., Andersen A., Korner A., Minthon L., Garraux G., Nelissen N., Bormans G., Buckley C., Owenius R., Thurfjell L., Farrar G., Brooks D.J. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann. Neurol. 2010, 68:319-329.
52. Welsh K.A., Butters N., Hughes J.P., Mohs R.C., Heyman A. Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer's Disease. Arch. Neurol. 1992, 49:448-452.
53. 1H magnetic resonance spectroscopy data. Magn. Reson. Med. 2011, 65:1-12.
54. Winblad B., Palmer K., Kivipelto M., Jelic V., Fratiglioni L., Wahlund L.O., Nordberg A., Bäckman L., Albert M., Almkvist O., Arai H., Basun H., Blennow K., de Leon M., DeCarli C., Erkinjuntti T., Giacobini E., Graff C., Hardy J., Jack C., Jorm A., Ritchie K., van Duijn C., Visser P., Petersen R.C. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J.Intern. Med. 2004, 256:240-246.
55. Wishart H.A., Saykin A.J., Rabin L.A., Santulli R.B., Flashman L.A., Guerin S.J., Mamourian A.C., Belloni A.C., Rhodes D.R., McAllister T.W. Increased brain activation during working memory in cognitively intact adults with the APOE epsilon4 allele. Am. J. Psychiatry 2006, 163:1603-1610.
56. Wolk D.A., Dickerson B.C. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A 2010, 107:10256-10261. Alzheimer's Disease Neuroimaging Initiative.
57. Zhu H., Barker P.B. MR spectroscopy and spectroscopic imaging of the brain. Magnetic resonance neuroimaging 2010, vol. 711:203-226. Humana Press, Totowa, NJ.